What is Decently?
Decently operates as a specialized medtech platform provider dedicated to the complex field of brain trauma management. Based in Manchester, the company integrates advanced data analytics with clinical workflows to improve patient outcomes and streamline neurological care. By focusing on the intersection of trauma diagnostics and digital health, Decently addresses a high-acuity market segment that requires precision, reliability, and scalable technological infrastructure. Its position as a key player in the UK's burgeoning health-tech ecosystem is bolstered by a commitment to evidence-based solutions that bridge the gap between acute clinical intervention and long-term patient recovery.
How much funding has Decently raised?
Decently has raised a total of $613K across 1 funding round:
Other Financing Round
$613K
Other Financing Round (2023): $613K with participation from SFC Capital, Bruntwood, and Praetura Ventures
Key Investors in Decently
SFC Capital
SFC Capital is a prominent UK-based seed investor that provides essential backing to early-stage businesses across diverse sectors, including biotech and fintech, leveraging an extensive angel syndicate.
Bruntwood
Bruntwood is a Manchester-headquartered property firm that supports regional business growth by providing specialized office and retail infrastructure for high-growth enterprises.
Praetura Ventures
Praetura Ventures is a venture capital firm focused on Northern England, known for providing both financial capital and operational expertise to help founders build resilient, high-growth businesses.
What's next for Decently?
With the successful closure of this major strategic investment, Decently is poised to transition into a phase of rapid operational scaling and product commercialization. The company is expected to prioritize the enhancement of its core platform capabilities, potentially expanding its diagnostic reach to encompass a broader spectrum of neurological conditions. Furthermore, the strategic alignment with its current investor base suggests a focus on strengthening its presence in Northern England's innovation hubs while exploring international market entry. As the firm matures, the emphasis will likely shift toward securing long-term clinical partnerships and integrating its technology into standard hospital protocols, thereby cementing its status as an essential component of modern neurological trauma care.
See full Decently company page
